The ① "base medicine" may usher in the sixth adjustment, which is expected to catalyze the volume of the traditional Chinese medicine industry, after the Health Commission included the proportion of the use of essential drugs in the assessment indicators. Analysts are optimistic that this adjustment is expected to be included in the children's medicine catalogue for the first time, and paediatrics proprietary Chinese medicine companies are more likely to benefit; ② microgrid ushered in the "policy + market" dual drive, the company's core product gross profit margin of 45% far higher than the industry, currently working on nearly 20, 000 projects.